Tengion rounds up $39M in new venture funds

Tengion has raised $39 million in its first round of venture capital. The King of Prussia, Pennsylvania-based company has been developing a technique to make new organs and tissues from patient's cells to replace damaged organs and tissues. "Based on more than 15 years of research and an extensive intellectual property foundation licensed from the Children's Hospital Boston, the pediatric teaching hospital of the Harvard Medical School and the Massachusetts Institute of Technology, Tengion is now well positioned to advance its science into the clinic," said Steven Nichtberger, MD, president and CEO of Tengion.

- read this press release for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.